

\$400,000 Reorder Booked for Products; Revenues Increased 1013% from \$254,686 to \$2,833,378: Endexx: Stock Symbol: EDXC

\$400,000 Reorder Booked for Non-Nicotine Vape Product After Company Reports Year-Over-Year Quarterly Revenues Increased 1013% from \$254,686 to \$2,833,378: EDXC

CAVE CREEK, ARIZONA, UNITED STATES, October 16, 2023 /EINPresswire.com/ -- \$400,000 Reorder Booked for Non-Nicotine Vape Product After Company Reports Year-Over-Year Quarterly Revenues Increased 1013% from \$254,686 to \$2,833,378: Endexx Corporation ([Stock Symbol: EDXC](#))

□ Developing and Marketing All Natural, Plant-Derived Wellness Products and Topical [Skincare Products](#).

□ Also Involved with Strategic Partners in the Entertainment, Marketing, and Distribution Arenas.

□ \$400,000 Reorder for Non-Nicotine Vape Product Hyla Highlights Hyla's Accelerating Product Demand.

□ Quarter Ending March 31, 2023, Showed Increasing Revenues Year-Over-Year of 1013% and Six Month Revenues Grew 528%.

□ Veteran Abbot Laboratories Sales Manager for Middle East and Africa Brings Industry Experience to EDXC.

Endexx Corporation ([OTCQB: EDXC](#)) develops and distributes all-natural, plant-derived wellness



CBD UNLIMITED™ A Pioneer and Trusted Name in CBD is Poised to Become the Fastest Growing CBD Company in 2021 **OTC: EDXC** Endexx Corporation

Endexx Corporation \$EDXC

Strength in Distribution Partners

CBD UNLIMITED™

CBD Unlimited™ has carefully partnered with the nation's largest wine and spirits distribution company. One out of every three bottles in stores nationally are distributed by SOUTHERN GLAZERS. A strong partnership allows CBDU to grow state by state.

CBD Unlimited™ "Over-the-Counter (OTC)" Topicals are located in WALGREENS and CVS Pharmacies

CVS pharmacy **SOUTHERN GLAZERS WINE & SPIRITS**

Walgreens

Stock Symbol : EDXC **TryHyla.com** **CBDunlimited.com**

\$EDXC #EDXC Partners

products and topical skincare products. EDXC products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind EDXC products involves a decade of clinical research in the field and lab work to provide a functional formulation with ingredients for optimal absorption and support of skin health.

The global beauty and wellness product market size was valued at USD 1,504.4 billion in 2022 and is projected to grow from USD 1,610.5 billion in 2023 to USD 2,765.8 billion by 2030, exhibiting a CAGR of 8.03% over the forecast period. Source: <https://www.fortunebusinessinsights.com/beauty-and-wellness-products-market-108456>.

EDXC is also involved in joint ventures with strategic partners in the entertainment, marketing, and distribution arenas. EDXC has made strategic acquisitions over the last several years that are now cohesively accelerating the company into its revenue growth stage.

“

For Hyla, securing this reorder in Italy not only underscores the demand for non-nicotine vape products but also reaffirms the strength and vitality of our distribution relationships”
\$EDXC CEO Todd Davis

EDXC Management Team and its advisory group each have a minimum of 10-50 years of experience in their respective fields. The EDXC professionals all have experience in growing businesses and developing, and implementing new consumer products and technologies with an emphasis in the medical, biotech, and life science industries.

EDXC-owned Hyla currently markets its proprietary non-nicotine, guarana, and L-Dopa-based vape products in a

wide variety of flavors. The EDXC Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Hyla is currently being distributed in 10 countries and has signed distribution

Growth Opportunities





MARKET OVERVIEW AND GROWTH

- ↳ Explosive Growth in Europe and Asia
- ↳ Sold 140,000 units inside of first 30 days
- ↳ #1 selling flavored, nicotine-free, disposable device brand in the US market

U.S. E-cigarette & Vape Market Report Scope

Report Attribute	Details
Market size value in 2021	USD 7.43 billion
Revenue forecast in 2018	USD 40.25 billion
Growth Rate	CAGR of 27.3% from 2021 to 2028
Base year of estimation	2020
Historical data	2016 – 2019
Forecast period	2021 – 2028

Stock Symbol : **EDXC**
TryHyla.com
CBDunlimited.com

\$EDXC Hyla Product



CLEAN. SAFE. SUSTAINABLE.

The sustainably sourced collection features 100% U.S. grown and processed hemp products that focus on a natural approach to achieving the healthiest hair and skin, which is essential for a man to feel at his prime.



OUR PRODUCTS. OUR PROMISE.

- Adherence to cGMP guidelines and protocols
- Adherence to Prop 65 guidelines
- Transparency in labeling
- Manufacturing through processes that minimize negative environmental impact
- Focus on the use of nutritious, sustainable, plant-based ingredients and safe synthetics as necessary for preservation or performance
- Emphasis on high performance key active ingredients that have been clinically studied
- High Impact visible results while still being kind to the skin
- The promise that they are Free of GMO's, parabens, micro-plastics, propylene or butylene glycol, Phthalates, DMDM, Urea, animal bi-products



Stock Symbol : **EDXC**
TryHyla.com
CBDunlimited.com

\$EDXC Clean and Safe

agreements with an additional nine countries.

The global e-cigarette and vape market size was estimated at USD 22.45 billion in 2022 and is expected to reach USD 28.17 billion in 2023. Source: <https://www.grandviewresearch.com/industry-analysis/e-cigarette-vaping-market>.

For more information on the EDXC Hyla project visit: www.endexx.com

The infographic titled "Hyla™ — Product Overview" features the Endexx logo in the top right corner. Below the title is the tagline: "Best in class organic, zero-nicotine, tobacco-free alternative vapes with first-mover advantage". The content is organized into three columns: "Alternative Experience", "Early Traction", and "Brand Expansion". To the right of these columns is a vertical stack of Hyla vape devices in various colors (pink, orange, green, yellow, red, brown). At the bottom, it lists the stock symbol "EDXC", the website "TryHyla.com", and "CBDunlimited.com".

Alternative Experience	Early Traction	Brand Expansion
<ul style="list-style-type: none">Flavored disposable vapes with no nicotine and no tobaccoUnique vegan and proprietary blend<ul style="list-style-type: none">Guarana plant extract contains naturally occurring caffeineHyla DOPA — new product with guarana and added benefit of L-DOPA, a dopamine building block	<ul style="list-style-type: none">Sold 950,000 Hyla devices from the acquisition date until the end of Q3 2023Completely sold out initial inventory to become the #1 selling flavored, nicotine-free, disposable device brand in US market	<ul style="list-style-type: none">Current products available for purchase in 11 states and 10 international marketsRetail availability increasing in domestic and international marketsDistribution partners in several countries

Stock Symbol : **EDXC** TryHyla.com CBDunlimited.com

\$EDXC Hyla Market

EDXC Secures Reorder for Non-Nicotine Vape Product Hyla From Italy \$400,000 Reorder Highlights Hyla's Accelerating Product Demand

On October 12th EDXC announced it had secured a reorder for its non-nicotine-based vape product, Hyla, from its distributor in Italy. This \$400,000 reorder represents a mix of the current DOPA 1200 puff device and the new 4500 puff device.

The new 4500 device is awaiting a final permit for Italy and will be shipped in the EDXC First Fiscal Quarter of 2024. The reorder marks the strengthening of EDXC relationships with its distributors and continues to show accelerated demand for Hyla products worldwide.

Report for The Quarter Ending March 31, 2023, Increasing Year-Over-Year 1013%

Endexx Year Over Year Six Month Revenues Grew 528%

On September 19th EDXC announced the filing of its amended, consolidated, audited 10-Q/A Quarterly report for the quarter ending March 31, 2023.

EDXC Milestones and Highlights for the quarter included:

Year-over-year quarterly revenues increased 1013% from \$254,686 to \$2,833,378.

For the six months ended March 31, 2023, EDXC recorded a 528% increase in revenue, from \$529,277 to \$3,326,087 Year-Over-Year for the same period.

Six-month losses year-over-year improved, March 31, 2023, were \$2,584,678 compared to \$4,426,299 in the same period of fiscal 2022.

EDXC CEO Todd Davis said, "Consolidating the audited financials and integrating Hyla's

operations into EDXC, we've catapulted into an era marked by unprecedented growth, painting Fiscal 2023 as a canvas of resurgence and robust expansion amidst a two-year stagnation in the industry. This synergy has not just revitalized our foothold in the domestic market but has also catapulted us onto the global stage, significantly multiplying our retail presence into 11 countries, particularly during the initial half of Fiscal 2023."

EDXC Provides Insight on Possible New Federal Regulations

Reclassification Under the Controlled Substances Act (CSA) Offers a New Pathway for Institutions and US Investment Banking to Participate in the Industry

On September 12th EDXC announced insight on the potential benefits of the new statements made concerning reclassification of specialty botanical products. Statements recently provided by the FDA and HHS to the DEA indicate a new policy stance at the Federal level versus the political theatre. A policy shift at the federal level provides a pathway forward for Research Institutions and US investment banking to finally participate in the industry.

'On August 29, 2023, the United States Department of Health and Human Services (HHS) recommended that the United States Drug Enforcement Administration (DEA) ease government restrictions on certain specialty botanicals. The HHS has recommended these products be rescheduled under the CSA from a Schedule I controlled substance to Schedule III controlled substance, following an extensive review by the United States Food and Drug Administration (FDA)."

Ultimately, the DEA has final authority with respect to rescheduling and will consider factors such as the history of abuse (e.g., scope, duration, patterns, etc.), the relative potential for abuse, and the risk to public health. DEA will also consider any scientific evidence (e.g., pharmacological effect, physiological dependence, etc.) regarding specialty botanicals.

Pathway to Potential Benefits for the specialty botanicals industry if reclassified:

Safer banking and management of cash.

Regulatory compliance simplification.

US Based Public company participation.

US Based Investment Banking and Capital Formation.

US Leadership in International Trade.

Physician Participation with Patients.

Institution and Academic Research.

EDXC Appoints Ahmed Itani to Director of Marketing of HYL A in The Middle East

On September 6th EDXC announced it has appointed Ahmed Itani to lead the company's HYL A marketing efforts in The Middle East region.

A seasoned professional with an impressive track record in the corporate world, Itani boasts 14 years of commercial healthcare sales experience and is a dynamic team player who has consistently excelled in driving business growth and fostering strong client relationships.

"Mr. Itani's wealth of experience, strategic vision, and commitment to success makes him a perfect match to lead HYL A's marketing efforts in The Middle East," said Todd Davis, CEO of EDXC. "We are excited to welcome Mr. Itani and continue to expand the HYL A team as the demand for plant-based products grows throughout the world."

Mr. Itani's career began at Abbott Laboratories, where he took charge of managing the commercial activities in The Middle East region. Through meticulous customer relationship management and astute distributor oversight, Itani played a key role in expanding Abbott Laboratories' presence in this vital market.

For more information on \$EDXC visit: www.endexx.com

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell, or offer to buy any security. CAP/FPS/CA's market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell, or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details that were previously disseminated by the companies mentioned in this release or the opinion of the writer. CAP/FPS/CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$500 by a third party for the dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include

the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In light of these uncertainties, the forward-looking events referred to in this release might not occur.

SOURCE: CorporateAds.com

Todd Davis, CEO
Endexx Corporation
+1 480-595-6900

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/662059605>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.